Triple drug combo benefits lupus nephritis

Triple drug combo benefits lupus nephritis

(HealthDay)—In a trial of 368 Chinese patients with lupus nephritis, those who were given a trio of medications were more likely to see a complete remission. The researchers, led by Zhihong Liu, M.D., of the Nanjing University School of Medicine in China, reported the findings online Nov. 11 in the Annals of Internal Medicine.

Liu's team randomly assigned patients with to one of two groups: One received monthly infusions of cyclophosphamide, plus oral steroid medication; the other received , along with two immune-suppressing medications—mycophenolate mofetil and tacrolimus.

After six months, 45.9 percent of patients on the drug trio were in complete remission, and 83.5 percent had at least a partial response. In contrast, 25.6 percent of patients on cyclophosphamide were in complete remission. And 63.0 percent had at least a partial response.

"Multitarget therapy provides superior efficacy compared with intravenous cyclophosphamide as induction therapy for lupus nephritis," the authors write.

More information: Full Article
Full Text (subscription or payment may be required)

Journal information: Annals of Internal Medicine

Copyright © 2014 HealthDay. All rights reserved.

Citation: Triple drug combo benefits lupus nephritis (2014, November 11) retrieved 28 November 2023 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

'Multi-target' immune therapy improves outcomes of severe lupus nephritis


Feedback to editors